Bioethics News

After Setbacks, a Pioneering Stem-Cell Technology’s Back in Human Trials

September 14, 2016

(MIT Technology Review) – A company that stepped in to salvage the first-ever medical use of human embryonic stem cells says it has encouraging results in patients with spinal-cord injury. Today, Asterias Biotherapeutics, the company in Fremont, California, that’s developing the treatment, will present data it says shows some gains of movement and sensation in five patients with spinal injuries who received injections of nervous system cells. The company’s technology is notable because of its link to the original discovery of human embryonic stem cells nearly 20 years ago.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.